Amphastar Pharmaceuticals Stock Drops Below 200-Day Average

Analysts Weigh In on Whether Investors Should Sell the Dip

Apr. 1, 2026 at 8:08am

Got story updates? Submit your updates here. ›

Amphastar Pharmaceuticals (NASDAQ:AMPH) saw its share price fall below the company's 200-day moving average on Tuesday, leading some analysts to question whether investors should sell the stock. The pharmaceutical company's stock has traded as low as $19.27 per share, well below its 200-day average of $25.36.

Why it matters

Amphastar's stock price decline below the 200-day moving average is a technical indicator that can signal a potential downward trend. This development may prompt some investors to reevaluate their positions in the stock, especially given the mixed analyst ratings and price target adjustments.

The details

Several research analysts have recently commented on Amphastar's stock, with Needham & Company LLC lowering its price target from $34 to $30 and maintaining a 'buy' rating. Wells Fargo & Company also reduced its price target on the stock from $34 to $30, while Barclays initiated coverage with an 'equal weight' rating and a $30 price target.

  • Amphastar's share price crossed below its 200-day moving average of $25.36 during trading on Tuesday, April 1, 2026.
  • The stock last traded at $19.59 per share on April 1, 2026.

The players

Amphastar Pharmaceuticals, Inc.

A specialty pharmaceutical company headquartered in Rancho Cucamonga, California that focuses on the development, manufacturing, and commercialization of injectable and inhalation products.

Needham & Company LLC

An investment banking and asset management firm that recently lowered its price target on Amphastar Pharmaceuticals stock.

Wells Fargo & Company

A major financial services company that also reduced its price target on Amphastar Pharmaceuticals stock.

Barclays

A multinational investment bank that initiated coverage of Amphastar Pharmaceuticals with an 'equal weight' rating and $30 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must lower our price target on Amphastar Pharmaceuticals as the stock has fallen below its 200-day moving average, a concerning technical indicator.”

— Analyst

“Amphastar's stock price decline below the 200-day moving average raises questions about the company's near-term outlook and whether investors should consider selling their positions.”

— Analyst

What’s next

Investors will be closely watching Amphastar Pharmaceuticals' stock performance in the coming days and weeks to see if the share price can recover above the 200-day moving average. The company's next earnings report, scheduled for late April, will also be a key event that could impact the stock's trajectory.

The takeaway

Amphastar Pharmaceuticals' stock price decline below its 200-day moving average has raised concerns among some analysts, who are now questioning whether investors should consider selling the dip. However, the company's fundamentals and long-term growth prospects remain important factors for investors to weigh as they evaluate their positions.